Experienced Clinical Database Programmer

Medpace slumps on solid report - where are the 'holes?' * ALLISON GATLIN * Updated 04:18 PM ET 10/22/2026 There were "no holes to poke" in Medpace Holdings' (MEDP) third-quarter earnings, an analyst said late Wednesday. And, on Thursday, Medpace stock recovered from its post-market malaise. All operating metrics topped expectations, Leerink Partners analyst Michael Cherny said in a report. The company also issued fourth-quarter guidance that came in ahead of analysts' current forecasts. Investors Are Rotating Into Healthcare. Here's Why. Janus Henderson portfolio manager Dan Lyons discusses why he sees opportunities for market outperformance in the healthcare sector as innovations in biotechnology, pharmaceuticals and medical devices proliferate. Investors Are Rotating Into Healthcare. Here's Why. See All Videos "Our best estimate, at least based off a weak/volatile aftermarket, is that implied expectations were higher due to the recent move in both the stock/CRO (contract resource organization) group, leaving a bar that maybe needed to be more overcome," he said. In after-hours trades Wednesday, Medpace stock dipped nearly 2% to 649.70. Ahead of the release, shares climbed 6.4%, closing at 662.48. On Thursday, the stock yo-yoed and closed down 1.3% at 653.96. Medpace shares are forming a cup base with a buy point at 677.90, MarketSurge shows. The stock has a nearly perfect Composite Rating of 97, meaning it trades in the top 3% of all stocks in terms of fundamental and technical measures. All key metrics top forecasts. During the three months ended Sept. 30, Medpace earned $4.84 a share on $716 million in sales. Earnings rose 25% to beat forecasts for $4.44 per share. Sales jumped about 8.5% and topped the Street's call for $714 million, according to FactSet. New orders came in at $873.4 million vs. forecasts for $852.3 million. The company's backlog was $3.17 billion, compared with projections for $3.13 billion. For the year, Medpace guided to earnings of $17.97 to $18.32 per share and $2.835 billion to $2.855 billion in sales. The Street called for $17.61 earnings per share on $2.85 billion in sales. "On the surface this does not feel like a negative surprise of any real magnitude, with the next leg of performance likely driven by where MEDP goes from here," Cherny said. He rates Medpace stock a market perform. IBD newsletters. Get exclusive IBD analysis and actionable news daily. Follow Allison Gatlin on X/Twitter at @AGatlin_IBD. YOU MAY ALSO LIKE:

Medpace (NASDAQ:MEDP) stock: insider August Troendle sells 26,701 shares. October 1, 2026 Key points. * CEO August Troendle sold 26,701 Medpace shares at an average price of $621.02, generating approximately $16.6 million. He retains 360,191 shares, a 6.9% reduction in his ownership. * Medpace shares recently traded at $598.08, with a market capitalization of $16.69 billion and a 52-week range of $373.00 to $677.90. * The company exceeded quarterly earnings and revenue expectations, while analysts maintain a consensus "Hold" rating with an average price target of $602.27. * Interested in Medpace? Here are five stocks we like better. Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) CEO August Troendle sold 26,701 shares of Medpace stock in a transaction dated Tuesday, September 29th. The shares were sold at an average price of $621.02, for a total transaction of $16,581,855.02. Following the sale, the chief executive officer owned 360,191 shares in the company, valued at approximately $223,685,814.82. This represents a 6.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Medpace stock performance. Shares of NASDAQ MEDP traded down $26.10 during trading on Thursday, hitting $598.08. The company had a trading volume of 232,765 shares, compared to its average volume of 330,847. The company has a market cap of $16.69 billion, a P/E ratio of 35.06, a PEG ratio of 2.78 and a beta of 1.15. The business's 50-day moving average is $600.14 and its 200 day moving average is $519.59. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90. Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to analysts' expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business's revenue for the quarter was up 17.2% on a year-over-year basis. During the same period last year, the company posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, research analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current year. Wall Street analyst weigh in. A number of research analysts have commented on MEDP shares. Royal Bank Of Canada boosted their target price on Medpace from $484.00 to $692.00 and gave the company an "outperform" rating in a research note on Friday, July 24th. Truist Financial lifted their price target on Medpace from $462.00 to $609.00 and gave the stock a "hold" rating in a research report on Friday, July 24th. Mizuho boosted their price target on Medpace from $586.00 to $665.00 and gave the company an "outperform" rating in a research note on Friday, July 24th. BMO Capital Markets upped their target price on shares of Medpace from $400.00 to $600.00 and gave the company a "market perform" rating in a research note on Friday, July 24th. Finally, Weiss Ratings raised shares of Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, August 12th. Three investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Medpace presently has a consensus rating of "Hold" and an average price target of $602.27. Discover more Financial News Financial Markets News Institutional investors weigh in on Medpace. Several large investors have recently bought and sold shares of MEDP. Johnson Financial Group Inc. bought a new stake in shares of Medpace in the 2nd quarter valued at $27,000. Jones Financial Companies Lllp acquired a new position in Medpace during the 2nd quarter worth approximately $30,000. Allied Private Wealth LLC bought a new position in Medpace in the second quarter valued at $31,000. Kilter Group LLC bought a new position in shares of Medpace in the 2nd quarter valued at about $31,000. Finally, Basecamp Wealth Advisors LLC grew its stake in Medpace by 187.5% in the first quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company's stock valued at $33,000 after purchasing an additional 45 shares in the last quarter. Institutional investors own 77.98% of the company's stock. About Medpace. Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities. Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Medpace, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list. While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

Boyds expands Regulatory Affairs team to support growing demand. Expansion and Company Growth Staff News 28 Sep 2026 Global drug development consultancy Boyds has strengthened its award-winning Regulatory Affairs team with the appointment of two senior specialists, further expanding its ability to support life sciences companies as they navigate increasingly complex regulatory pathways. Established in 2005, Boyds works with an international client base to help translate scientific innovation into medicines and medical devices for patient benefit. Vicki Hayes joins Boyds as Vice President of Regulatory Affairs and Jan Ohotski joins as Director of Regulatory Affairs. Together, they bring senior expertise spanning global regulatory strategy, clinical development, small molecules, biotechnology therapeutics, and cell and gene therapies. Vicki brings more than 20 years' experience in regulatory affairs and joins Boyds from a US biotechnology company, where she was Vice President of Global Regulatory Affairs and Policy. She was previously a Board Director at a regulatory affairs consultancy, where she held several senior regulatory affairs roles, and has also worked at Amgen and Eli Lilly and Company. She has created and led regulatory strategies from first-in-human studies through to post-licensing across therapeutic areas including oncology, neuroscience, anti-infectives and rare diseases, and across modalities including small molecules, biologics and advanced therapies. In 2022, Vicki was awarded the TOPRA Regulatory Affairs Contribution Award. At Boyds, Vicki will lead the regulatory consulting function, working closely with clients to design robust, pragmatic regulatory strategies that support product development decisions. Commenting on her appointment, Vicki said: "Boyds thinks outside the box and provides a bespoke, tailored service that supports the development of novel, emerging and cutting-edge technologies. As Vice President of Regulatory Affairs, I look forward to developing creative and pragmatic regulatory strategies that accelerate development and maximise product value, as well as working with the award-winning Regulatory Affairs team, many of whom I have had the pleasure of working with previously." Jan joins Boyds from CRO Medpace, where he led the Cell and Gene Therapy team. He began his career as a scientist focused on drug discovery and pharmacology for oncological indications, working in both academia and industry, before moving into regulatory affairs more than ten years ago. He specialises in the clinical development of cell and gene therapies and, at Boyds, will support regulatory affairs activities alongside clinical operations. Jan commented: "Boyds is known in the industry for its impactful work on cutting-edge medicines, including cell and gene therapies. My interest in these therapies, along with my desire to further develop my expertise in regulatory consulting, attracted me to Boyds. I look forward to bringing practical operational knowledge across the non-clinical, clinical and CMC development of cell and gene therapies, including global expertise in biosafety risk assessments and associated submissions." Dr Katherine Bowen, Chief Regulatory Affairs Officer at Boyds, said: "We are delighted to welcome Vicki and Jan to Boyds. Their combined experience further strengthens our ability to provide strategic and practical regulatory support to clients developing innovative medicinal products. "Demand is rising as clients face complex regulatory challenges and need expert support to keep programmes moving efficiently. Our Regulatory Affairs team has built long-standing, trusted relationships with leading regulators, founded on decades of regulatory experience and constructive engagement. The appointment of Vicki and Jan further solidifies these relationships, enabling productive, solution-focused discussions that help clients anticipate requirements, address regulatory questions and move development programmes forward."